Several urged for increased education and awareness among healthcare providers to reduce stigma when treating HIV patients in ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

Later, another study (PURPOSE-2) showed that lenacapavir reduced HIV infections by 96% compared to background HIV incidence ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Dr. Colleen Kelley, principal investigator for PURPOSE 2, emphasized the jab's effectiveness, "When compared to the background HIV incidence... lenacapavir reduced HIV infections by 96%." She added, ...

“Ensuring that all individuals, irrespective of socioeconomic background, origin, or identity, have equal access to HIV prevention, treatment, and care is essential. Universal health coverage is ...